Remove Bioavailability Remove Containment Remove Development Remove Medicine
article thumbnail

Solving pharma’s process development challenges one API at a time

Pharmaceutical Technology

The potential to use these scientific breakthroughs to make a real difference to patients’ lives is what drives many highly skilled scientists to the world of drug development. This is where the process development stage, which directly follows the drug discovery and early formulation work, can make or break a drug’s success.

article thumbnail

PureTech Reveals New CBD Pill to Rival Jazz’s Epidiolex

XTalks

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Jazz bought out Epidiolex developer GW Pharmaceuticals for the drug in a whopping $7.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthesis-to-Clinic®: integrating isotopic labeling and human ADME to reduce time to clinic

Pharmaceutical Technology

Few contract development and manufacturing organizations (CDMOs) are able to provide radiolabeling services as part of a fully integrated pharmaceutical development program. How does your unique Synthesis-to-Clinic® offering streamline the drug development process?

article thumbnail

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

article thumbnail

Polymorph profiling with X-ray powder diffraction protects patents and patients

Drug Discovery World

A recent report indicated the current market size to be ~$166 billion, and a 4% compound annual growth rate is set to take the sector to a worth of $210 billion by 2 028 , offering an attractive landscape for developers. . Polymorphic perils and possibilities.

article thumbnail

Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc.

The Pharma Data

Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions.

article thumbnail

Nanoform launches technology for biologics and sets new near-term business target for 2021

The Pharma Data

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Nov. ” Prof.